Development of diabetes after gatifloxacin therapy

American Journal of Health-System Pharmacy

Volumn 62, Issue 21, 2005, Pages 2293-2295

  Stading, Julie A ^a   Chock, Alan W Y ^a   Skrabal, Maryann Z ^a   Faulkner, Michele A ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMOXICILLIN PLUS CLAVULANIC ACID; BUTALBITAL; DIPHENHYDRAMINE; DOCUSATE SODIUM; FUROSEMIDE; GATIFLOXACIN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; INDOMETACIN; INSULIN; SIMVASTATIN;

ADULT; ANTIBIOTIC THERAPY; CASE REPORT; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LEG ULCER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 27644543237     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050119     Document Type: Review

References (4)

1. Tequin (gatifloxacin) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2004 Nov.
2. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
3. Arce FC, Bhasin RS, Pasmantier R. Severe hyperglycemia during gatifloxacin therapy in patients without diabetes. Endocr Pract. 2004; 10:40-4.
4. Donaldson AR, Vandiver JR, Finch CK. Possible gatifloxacin-induced hyperglycemia. Ann Pharmacother. 2004; 38:602-5.